<DOC>
	<DOCNO>NCT02655237</DOCNO>
	<brief_summary>The purpose study evaluate efficacy TAK-385 40 mg administer orally daily 12 week , compare leuprorelin injection ( once/4 week , 1.88 mg 3.75 mg SC/time ) participant uterine fibroid .</brief_summary>
	<brief_title>A Phase 3 Study Evaluate Efficacy Safety TAK-385 40 mg Compared With Leuprorelin Treatment Uterine Fibroids</brief_title>
	<detailed_description>This phase 3 , multicenter , randomize , double-blind , parallel-group , non-inferiority study evaluate efficacy safety TAK-385 administer orally daily dose 40 mg 24 week , compare leuprorelin injection ( once/4 week , 1.88 mg 3.75 mg subcutaneous [ SC ] /time ) premenopausal participant ≥ 20 year age symptomatic uterine fibroid . The primary objective study evaluate efficacy TAK-385 40 mg administer orally daily 12 week . Participants must diagnose uterine fibroid confirm transvaginal ultrasound method , symptom menorrhagia . The total number participant randomize double-blind condition 288 ( 144 participant TAK-385 40 mg group leuprorelin group ) .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Inclusion Criteria Entering Screening ( VISIT 1 ) 1 . In opinion investigator subinvestigator , participant capable understand comply protocol requirement . 2 . The participant sign date write , informed consent form prior initiation study procedure . 3 . Prior VISIT 1 , participant diagnosis uterine fibroid confirm transvaginal ultrasound , abdominal ultrasound , magnetic resonance imaging ( MRI ) , compute tomography ( CT ) , laparoscopy , never receive surgical treatment myoma ( measurable noncalcified myoma long diameter ≥ 3 cm ) . 4 . The participant premenopausal Japanese woman . 5 . The participant age 20 year old day sign date informed consent form . 6 . The participant 1 measurable noncalcified myoma long diameter ≥ 3 cm confirm transvaginal ultrasound . 7 . The participant experience 1 regular menstrual cycle ( 25 38 day ) immediately prior VISIT 1 include menstrual bleeding least 3 consecutive day . 8 . The participant sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study . Inclusion Criteria Entering Runin ( VISIT 2 ) 9 . The participant experience regular menstrual cycle ( 25 38 day ) immediately prior VISIT 2 include menstrual bleeding least 3 consecutive day ( least 2 regular menstruation cycle confirm Inclusion criterion # 7 # 9 ) . Inclusion Criteria Entering Treatment ( VISIT 3 ) 10 . The participant 1 measurable noncalcified myoma , long diameter ≥ 3 cm confirm transvaginal ultrasound ( myoma measure Inclusion criterion # 6 ) . 11 . The participant diagnosis menorrhagia total PBAC score ≥ 120 1 menstrual cycle VISIT 3 . 12 . The participant experience regular menstrual cycle ( 25 38 day ) VISIT 1 include menstrual bleeding least 3 consecutive day ( least 3 regular menstruation cycle confirm Inclusion criterion # 7 , # 9 # 12 ) . 1 . The participant receive investigational compound within 24 week prior start administration study medication Runin ( VISIT 2 ) . 2 . The participant receive TAK385 ( include placebo ) previous clinical study . 3 . The participant immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . The participant previous current history blood disorder ( eg , thalassemia , sickle cell anemia , folicacid deficiency , coagulopathy ) , exclude ( latent ) irondeficiency anemia . 5 . The participant known history severe hypersensitivity severe allergy sanitary good . 6 . The participant lower abdominal pain due irritable bowel syndrome severe interstitial cystitis . 7 . The participant current history thyroid gland disorder irregular menstruation , potential irregular menstruation due thyroid gland disorder , determine investigator subinvestigator . 8 . The participant previous current history pelvic inflammatory disease within 8 week prior VISIT 1 . 9 . The participant positive Pap smear test result conduct within 1 year prior VISIT 1 ( previous test result , judge positive test conduct VISIT 2 ) . 10 . The participant history panhysterectomy bilateral oophorectomy . 11 . The participant markedly abnormal uterine bleed anovulatory bleeding , determine investigator subinvestigator . 12 . The participant malignant tumor history malignant tumor within 5 year prior VISIT 1 . 13 . The participant treat follow drug ( exclude drug external use dietary supplement ) within 4 week prior VISIT 2 : anticoagulant drug , antiplatelet drug , tranexamic acid , selective estrogen receptor modulators ( SERMs ) , activate vitamin D preparation , vitamin D preparation , calcitonin , ipriflavone , steroid hormone , vitamin K preparation , teriparatide , denosumab . 14 . The participant treat follow drug within 8 week prior VISIT 2 : oral contraceptive sex hormone preparation ( norethindrone , norethisterone , medroxyprogesterone , estrogen , progestin ) , within 16 week prior VISIT 2 : gonadotropinreleasing hormone ( GnRH ) analogue , dienogest , danazol , aromatase inhibitor ( 1 3month sustainedrelease preparation , within 20 28 week prior VISIT 2 , respectively ) . 15 . The participant treat bisphosphonate preparation within 24 week prior VISIT 2 . 16 . The participant previous current history hypersensitivity allergy leuprorelin , synthetic GnRH , GnRH agonists GnRH antagonist , previous current history severe hypersensitivity severe allergy drug . 17 . The participant nondiagnosable abnormal genital bleeding . 18 . Female participant pregnant , lactating , intend become pregnant donate ovum prior sign inform consent , study period , within 1 month end study . 19 . The participant previous current history osteoporosis , osteopenia , metabolic bone disease . 20 . The participant clinically significant cardiovascular disease ( eg , myocardial infarction unstable angina pectoris within 24 week prior VISIT 1 ) uncontrollable hypertension ( eg , rest systolic blood pressure ≥ 180 mmHg diastolic blood pressure ≥ 110 mmHg Screening Runin ) . 21 . The participant inappropriate participation study base standard 12lead electrocardiogram ( ECG ) finding , determine investigator subinvestigator . 22 . The participant active liver disease jaundice , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , bilirubin ( total bilirubin ) &gt; 1.5 time upper limit normal ( ULN ) clinical laboratory test VISIT 1 2 . 23 . The participant previous current history disease consider inappropriate participation study , include severe hepatic impairment , jaundice , renal impairment , cardiovascular disease , endocrine system disease , metabolic disorder , pulmonary disease , gastrointestinal disease , neural disease , urological disease , immune disease , mental disorder ( especially depressionlike symptom ) suicide attempt result mental disorder . 24 . The participant previous current history drug abuse ( define illicit drug use ) alcohol abuse . 25 . The participant inappropriate participation study reason , determine investigator subinvestigator .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>